Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the introduction of the AccuLift™ Laser Capture Microdissection System. Ideal for translational and clinical pathology research, the new AccuLift product portfolio enables precise and efficient capture of individual cells or larger tissue regions for DNA, RNA and protein biomarker analysis.
You Might Also Like
Codex DNA Releases New Synthetic Genomes for the Fight Against COVID-19
Quanterix To Provide Research Use Access To The P217+Tau Assay Through Quanterix Accelerator Services Laboratory